Overview

• The CIN-based assay analyzes chromosomal gain, loss and rearrangement patterns to forecast patient responses to agents such as platinum compounds, taxanes and anthracyclines.
• Retrospective validation leveraged genomic and clinical data from more than 800 patients with breast, prostate, ovarian and sarcoma cancers.
• Developers secured funding from Spain’s Ministry for Digital Transformation and EU NextGenerationEU to support hospital validation studies and clinical rollout.
• Partnerships with Tailor Bio and 12 de Octubre University Hospital will operationalize prospective trials in real-world oncology settings.
• The assay is compatible with existing genomic sequencing platforms to facilitate seamless integration into routine cancer diagnostics.